Entering text into the input field will update the search result below

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

Jul. 05, 2022 6:07 AM ETDr. Reddy's Laboratories Limited (RDY)By: Ravikash, SA News Editor

Business agreement

mediaphotos/iStock via Getty Images

  • Dr. Reddy's Laboratories said its unit Aurigene, and EQRx are collaborating to develop drug candidates for cancer and immune-inflammatory diseases.
  • Under the agreement, Aurigene will use its small molecule drug discovery platform and will lead drug discovery and pre-clinical development efforts while EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.
  • The companies said they would share funding on development and any commercialization of potential drug candidates.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.